The Food and Drug Administration revoked approval for Genentech Inc.'s breast cancer drug Avastin, the agency said Friday.
In a statement, FDA Commissioner Margaret Hamburg said she is revoking the agency's approval of Avastin, also known as bevacizumab, after concluding the drug was not safe and effective in combatting metastatic breast cancer.
Avastin will remain on the market for types of colon, lung, kidney and brain cancer.
No comments:
Post a Comment